Shares of Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) reached a new 52-week low on Monday . The company traded as low as C$1.57 and last traded at C$1.70, with a volume of 87404 shares traded. The stock had previously closed at C$1.73.
Cardiol Therapeutics Trading Up 4.1 %
The company has a quick ratio of 6.84, a current ratio of 2.49 and a debt-to-equity ratio of 1.59. The firm has a market cap of C$146.87 million, a P/E ratio of -3.48 and a beta of 0.70. The business's 50 day moving average is C$1.86 and its 200-day moving average is C$2.32.
Insider Transactions at Cardiol Therapeutics
In other Cardiol Therapeutics news, Senior Officer Andrew Warwick Hamer purchased 18,900 shares of Cardiol Therapeutics stock in a transaction dated Thursday, December 19th. The shares were bought at an average cost of C$1.88 per share, for a total transaction of C$35,606.69. Also, Senior Officer Guillermo Torre bought 17,240 shares of the firm's stock in a transaction on Thursday, December 26th. The stock was bought at an average price of C$1.81 per share, with a total value of C$31,277.77. In the last 90 days, insiders purchased 86,140 shares of company stock valued at $161,456. Insiders own 4.57% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Further Reading
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
